Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death

Transplant International

Volumn 21, Issue 7, 2008, Pages 625-636

  Schadde, Erik ^b   D'Alessandro, Anthony M ^a   Knechtle, Stuart J ^a   Odorico, Jon ^a   Becker, Yolanda ^a   Pirsch, John ^a   Sollinger, Hans ^a   Fernandez, Luis A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Alemtuzumab; Campath 1H; Graft survival; Induction; Kidney transplantation; Rejection

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; CLOTRIMAZOLE; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; DAPSONE; DEXAMETHASONE; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PENTAMIDINE; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; AFRICAN AMERICAN; ARTICLE; BACTERIAL INFECTION; BK VIRUS; CADAVER DONOR; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE COST; HEART DEATH; HERPES; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTILYMPHOCYTE SERUM; CYTOMEGALOVIRUS INFECTIONS; DEATH; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RISK FACTORS; TISSUE DONORS;

EID: 45449086891     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00642.x     Document Type: Article

References (23)

1. Cho YW, Terasaki PI, Cecka JM, Gjertson DW. Transplantation of kidneys from donors whose hearts have stopped beating. N Engl J Med 1998 338 : 221.
2. Weber M, Dindo D, Demartines N, Ambuhl PM, Clavien PA. Kidney transplantation from donors without a heartbeat. N Engl J Med 2002 347 : 248.
3. Cooper JT, Chin LT, Krieger NR, et al. Donation after cardiac death: the university of wisconsin experience with renal transplantation. Am J Transplant 2004 4 : 1490.
4. Brennan D. Thymoglobulin Induction Study Group. Thymoglobulin versus simulect for induction immunosuppression in cadaveric renal transplant recipients: final results from a prospective, randomized, multicenter trial. Am J Transplant 2003 3 : 1268.
5. Flechner SM, Feng J, Mastroianni B, et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 2005 79 : 926.
6. Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995 59 : 1683.
7. Chapman J, Bock A, Dussol B, et al. Follow-up after renal transplantation with organs from donors after cardiac death. Transpl Int 2006 19 : 715.
8. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004 364 : 1814.
9. Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. BioDrugs 2005 19 : 39.
10. Bunnapradist S, Takemoto SK. Multivariate analyses of antibody induction therapies. Clin Transpl 2003 1 : 405.
11. Wilson CH, Brook NR, Gok MA, Asher JF, Nicholson ML, Talbot D. Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants. Br J Surg 2005 92 : 681.
12. Rivera CF, Hernandez AA, Verdejo PV, Garcia JO, Rego SC, Canedo FV. Basiliximab (Simulect) in acute tubular necrosis high-risk kidney transplantation. Transplant Proc 2005 37 : 3733.
13. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005 5 : 1347.
14. Knechtle SJ, Pirsch JDH, Fechner JJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003 3 : 722.
15. Barth RN, Janus CA, Lillesand CA, et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006 19 : 885.
16. Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005 5 : 3009.
17. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003 76 : 120.
18. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005 200 : 505 quiz A59-61.
19. Helderman J, Gilmore A, Marehbian J, Legorreta A. Patient outcomes assessment of campath induction therapy in renal transplant recipients. Transplantation 2006 82 : 294.
20. Huang E, Bunnapradist S. Alemtuzumab induction in kidney transplantation. Clin Transpl 2005 1 : 343.
21. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006 19 : 705.
22. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004 136 : 754.
23. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction-long-term results. Am J Transplant 2005 5 : 2539.